Enjoy complimentary customisation on priority with our Enterprise License!
The global liver cirrhosis therapeutics market size is estimated to grow by USD 1.94 billion at a CAGR of 5.58% between 2023 and 2028.
The global liver cirrhosis therapeutics market is being driven primarily by the rising incidence of liver diseases, particularly hepatitis and NAFLD. According to the World Health Organization (WHO) estimates, about 325 million people worldwide suffer from viral hepatitis alone, which raises the risk of liver cirrhosis. Moreover, the spike in metabolic syndrome and obesity-related disorders, including NAFLD, is driving up the need for efficient treatments. For example, the prevalence of NAFLD is increasing, impacting about 25% of the world's population. This highlights the need for sophisticated and easily available therapies. As a result of the increasing risk of cirrhosis associated with certain liver diseases, the global is expected to expand during the forecast period.
To learn more about this report, Request Free Sample
The market share growth by the oral segment will be significant during the forecast period. The oral type emerges as the market leader in the dynamic global market, indicating a paradigm shift in therapeutic approaches. Oral medications are becoming increasingly popular because of their patient-friendly qualities.
Get a glance at the market contribution of various segments Download PDF Sample
The oral segment was the largest and was valued at USD 3.81 billion in 2018. One example of an innovative drug is Obet cholic acid. Oral therapies such as medicines for non-alcoholic fatty liver disease (NAFLD) and antifibrotic medications are in high demand as people prioritize convenience and ease of administration. This development is being driven by industry efforts to improve treatment adherence in addition to patient preferences. The development of novel oral formulations that target particular pathways in the evolution of liver cirrhosis highlights the effectiveness and promise of this therapeutic strategy. This market scenario highlights an optimistic tendency and positions oral treatments as a key segment in the evolving market in focus. This, in turn, will drive the growth of global liver cirrhosis therapeutics during the forecast period.
The global market is expected to be dominated by hospitals as the primary distribution channel. Hospitals' pivotal role in patient care and treatment is driving this expansion. Hospitals enable easy access to liver cirrhosis therapeutics by providing a wide range of medical services under one roof. Prominent medical centres such as Cleveland Clinic and Mayo Clinic are noteworthy instances of the way they use their expertise to improve liver cirrhosis therapeutics. Hospitals remain a primary distribution channel for liver cirrhosis therapeutics, as evidenced by the faith that patients have in hospital-based healthcare. Such factors are expected to increase the adoption of hospitals as a distribution channel and hence drive the growth of the liver cirrhosis therapeutics market during the forecast period.
For more insights about the market share of various regions Download PDF Sample now!
North America is estimated to contribute 41% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. The regional market is expanding rapidly, propelled by factors such as the increased prevalence of liver disorders, growing public awareness, and sophisticated healthcare infrastructure. Over 630,000 persons were diagnosed with liver cirrhosis in the US alone in 2020, as the condition's incidence has been rising gradually. The increasing load has encouraged pharmaceutical companies to spend on R and D, which has resulted in the release of novel treatments. Drugs like Obet cholic acid, which have the approval of the FDA to treat liver fibrosis brought on by non-alcoholic steatohepatitis (NASH), are witnessing a sharp increase in use in the regional market.
In addition, the regional market's growth is further aided by the existence of major players like Gilead Sciences and Intercept Pharmaceuticals, as well as tactical alliances between drug manufacturers and healthcare providers. The region's dedication to developing medicinal solutions and meeting the growing healthcare needs related to liver cirrhosis is demonstrated by the rise of the market in focus, which in turn is expected to drive the growth of the regional liver cirrhosis therapeutics market during the forecast period.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 18 market companies, including:
Alnylam Pharmaceuticals Inc. - The company offers liver cirrhosis therapeutics such as siRNA-based targeted therapy to restore functional liver cells in patients with end-stage liver diseases.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the trends, and challenges.
The trend towards personalized medicine is an emerging trend shaping the market growth. Customizing treatment plans based on unique patient characteristics, such as genetic composition, liver function, and medication response, is a trend toward personalized medicine in the global market. This strategy seeks to maximize therapeutic results, reduce side effects, and improve patients' general quality of life. Genetic profiling, for example, can pinpoint precise biomarkers that impact drug metabolism, making it possible to prescribe the most effective drugs for a certain patient. With a more focused and specific approach to therapy, this trend represents a move away from a one-size-fits-all strategy and towards better patient outcomes and higher therapeutic efficacy.
Moreover, the global market is undergoing a paradigm change towards more personalized and patient-centred therapy as precision medicine continues to progress. Hence, the trend toward personalized liver cirrhosis therapeutics is expected to drive the growth of the market during the forecast period.
The high cost of liver cirrhosis therapeutics is a significant challenge hindering market growth. A major challenge in the global market is the high cost of liver cirrhosis therapeutics, which prevents certain patient groups from accessing them. Immunosuppressants and antiviral medications for hepatitis may need extensive courses, which adds significantly to the cost of care. Furthermore, sophisticated treatments such as liver transplantation, which may be a curative measure for end-stage cirrhosis, come with extremely high expenses associated with the surgery, the recovery period following the procedure, and the lifetime immunosuppressive drugs. People who live in areas with minimal healthcare resources or who have limited healthcare coverage are disproportionately affected by this financial hardship.
For instance, the cost barrier keeps many people from getting timely and effective liver cirrhosis therapies in underdeveloped nations, where affordability is a major concern. This exacerbates health disparities globally. Hence, the high cost of liver cirrhosis therapeutics is expected to be a constraint for the wide-scale adoption of liver cirrhosis therapeutics, which, in turn, will hinder the growth of the market during the forecast period.
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Market Customer Landscape
In the realm of hepatology, addressing liver disease treatment is paramount, particularly in combating cirrhosis medications. As fibrosis progression leads to hepatic decompensation and liver failure management, effective interventions are crucial. The market for liver health solutions, including hepatoprotective agents and antifibrotic therapies, is witnessing significant growth, driven by escalating cases of alcoholic liver disease and viral hepatitis treatment needs.
Market research and growth indicate a promising trajectory for ascites treatment and managing portal hypertension and hepatic encephalopathy. Innovative approaches to liver regeneration offer hope for patients. Market forecasting underscores the importance of strategic planning in this evolving landscape, where advancements in liver damage therapeutics continue to emerge, shaping the future of liver cirrhosis therapeutics.
The market report forecasts market growth analysis by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028.
Market Scope |
|
Report Coverage |
Details |
Page number |
154 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 5.58% |
Market Growth 2024-2028 |
USD 1.94 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
4.57 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 41% |
Key countries |
US, Germany, UK, Japan, and China |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
AbbVie Inc., Alnylam Pharmaceuticals Inc., Astellas Pharma Inc., AstraZeneca Plc, CSL Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Gwo Xi Stem Cell Applied Technology, Johnson and Johnson, Kezar Life Sciences Inc., Merck KGaA, Novartis AG, Novo Nordisk AS, Pfizer Inc., Protagonist Therapeutics Inc., and Tessera Therapeutics |
Market dynamics |
Parent market analysis, market growth and forecasting inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.